郑燕敏

摘 要 本文通过对我国临床用抗哮喘药物的市场数据分析，认为其市场规模持续较高增长，吸入用药为抗哮喘药物的主流剂型，跨国公司的原研产品用药金额在该品类中遥遥领先。研发进展剖析出后续产品将更多地向局部用药和多环节抑制哮喘发作方向发展。葛兰素史克、阿斯利康和罗氏在上述亚类中都有产品处于研发阶段，国内厂家需加快上述产品的技术更新。

关键词 支气管哮喘 市场 研发

中图分类号：R974.3 文献标识码：C 文章编号：1006-1533（2014）15-0076-04

Market analysis and research progress of anti-asthmatic drugs

ZHENG Yanmin

（Shanghai Sine Pharmaceutical Co. Ltd.， Shanghai 200436， China）

ABSTRACT Bronchial asthma is a kind of chronic respiratory disease and its incidence in China is increasing. The clinical use， situation and market data of asthma drugs were analyzed. It is showed that the market size had been steadily enlarging at higher speed and inhaled medication was the main dosage form for asthma drugs. The sales of branded products by multinational corporation were in a leading position in this category. Their subsequent products will be more and more trended to the local administration and to be developed in the direction of suppressing an asthma attack. There are some products at different development stage in GSK， AstraZeneca and Roche companies. Domestic manufacturers should speed up the technical update for the production of asthma drugs.

KEY WORDS bronchial asthma； market； research and development

支气管哮喘是一类慢性呼吸道疾病，目前国内发病率不断增高，治疗该病的主要是抗炎类和支气管扩张类药物。国内抗哮喘药物市场规模2012年已达132.79亿元，激素类、黄嘌呤类、β2-受体激动剂与肾上腺皮质激素联合用药这3个类别占据中高端用药市场的前三位，从用药途径上来看，吸入为主要方式，原研产品依然占据较大优势。各类研发资料显示，抗哮喘药物的新型品种在长效β2-受体激动剂+吸入性激素、单克隆抗体、黏附分子拮抗剂方面有所发展，葛兰素史克等跨国巨头在上述亚类中都有产品处于研发阶段，国内厂家需充分运用原有局部用药剂型优势，加速跟上该类药物技术更新的步伐。

抗哮喘药物临床应用现状

由于哮喘发病机制的复杂性，目前哮喘的治疗主要是通过控制症状，防止病情恶化，尽可能保持肺功能正常，防止不可逆气流阻塞，避免死亡[1]。

目前，抗哮喘药物可分为两类：一为抗炎症类的糖皮质激素类药物、抗白三烯药物、炎症介质阻释剂和拮抗剂等；……